Uracil Mustard

Summary

Uracil Mustard (CHEMBL1488) is an approved small molecule (ATC L01AD08); indicated across 1 condition including neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01AD08
• Indications: 1 condition
• Chemistry: 252.09 Da · C8H11Cl2N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1488
Name	Uracil Mustard
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6194
ChEBI	CHEBI:9884
ATC	L01AD08
Molecular formula	C8H11Cl2N3O2
Molecular weight	252.09
InChIKey	IDPUKCWIGUEADI-UHFFFAOYSA-N

SMILES: C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl

IUPAC name: 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione

Also known as: NSC-34462, U-8344, Uracil mustard, Uramustina, Uramustine, Chloroethylaminouracil, SID29216259, Uracil Mustard, URACIL MUSTARD, SID92079, URAMUSTINE, SID144205464

Patent coverage: 13,782 distinct patent families (59,928 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 59,833 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).